|
Thrombocythemia, Essential
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Deregulation of apoptosis-related genes is associated with PRV1 overexpression and JAK2 V617F allele burden in Essential Thrombocythemia and Myelofibrosis.
|
22300941 |
2012 |
|
Thrombocythemia, Essential
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
We also examined the expression of polycythemia rubra vera-1 (PRV-1), which is a diagnostic marker for clonal ET.
|
18802948 |
2008 |
|
Thrombocythemia, Essential
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
In polycythemia vera (PV) and essential thrombocythemia (ET) specific JAK2 mutations constitutively activate the JAK-STAT pathway, explaining biologic findings such as endogenous erythroid colony (EECs) growth or PRV-1 RNA overexpression.
|
18623127 |
2008 |
|
Thrombocythemia, Essential
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Children and adults with sporadic ET showed a similar proportion of patients with PRV-1 RNA overexpression, JAK2 V617F mutation, and clonality, while none of the familial ET showed JAK2 V617F mutation and clonality.
|
17369568 |
2007 |
|
Thrombocythemia, Essential
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
The use of biological markers including JAK2 V617 PCR test, serum EPO, PRV-1, EEC, leukocyte alkaline phosphatase score and peripheral blood parameters combined with bone marrow histopathology has a high sensitivity and specificity (almost 100%) to diagnose the early and overt stages of ET, PV and CIMF in JAK2 V617F positive and negative MPDs.
|
16919893 |
2007 |
|
Thrombocythemia, Essential
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Increased PRV-1 expression was found in 37 out of 46 patients diagnosed with PV (80%), in 4 out of 15 patients diagnosed with essential thrombocythemia (ET) (27%) and in 4 out of 8 patients with chronic idiopathic myelofibrosis (CIMF) (50%), and increased PRV-1 expression plus EEC formation was observed in 19 of 36 examined MPD patients indicating the superiority of PVSG and WHO bone marrow criteria for the diagnosis of ET, PV and CIMF.
|
17852451 |
2007 |
|
Thrombocythemia, Essential
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Furthermore, overexpression of the PRV-1 gene in PV and ET is associated with a decrease in methylation of this gene.
|
17976520 |
2007 |
|
Thrombocythemia, Essential
|
0.100 |
Biomarker
|
disease |
BEFREE |
Levels of the mutation were significantly higher in polycythemia vera compared with essential thrombocythemia (P=0.0005) and correlated with the following jointly significant variables at diagnosis: PRV-1, hemoglobin, white cell count, neutrophil count, and red cell count, using multiple regression analyses (P=0.015).
|
17384217 |
2007 |
|
Thrombocythemia, Essential
|
0.100 |
Biomarker
|
disease |
BEFREE |
PRV-1 (polycythemia rubra vera-1), TPO (thrombopoietin), and c-MPL (myeloproliferative leukemia virus oncogene) genes are candidate ET molecular markers because of their implication in the pathogenesis of ET.
|
16682284 |
2006 |
|
Thrombocythemia, Essential
|
0.100 |
AlteredExpression
|
disease |
LHGDN |
PRV-1 overexpression is the first reliable molecular marker of these myeloproliferative disorders, and its detection allows us to discriminate PV and ET from secondary erythrocytosis and thrombocytosis.
|
16502591 |
2006 |
|
Thrombocythemia, Essential
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
In order to explore the correlation between these two biological markers and compare their diagnostic utility, mutation analysis for JAK2(V617F) and quantitative measurement of granulocyte PRV-1 expression were performed on the same study sample from 100 participants: 38 with PV, 22 with essential thrombocythaemia (ET), 10 with agnogenic myeloid metaplasia (AMM), 19 with secondary polycythaemia (SP) and 11 healthy volunteers.
|
16197445 |
2005 |
|
Thrombocythemia, Essential
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Here, we compare PRV-1 expression and EEC formation in a cohort of 30 patients with ET; 50% of the ET patients in our cohort displayed EEC growth.
|
15034760 |
2004 |
|
Thrombocythemia, Essential
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
The effects of hydroxyurea on PRV-1 expression in patients with essential thrombocythemia and polycythemia vera.
|
15477215 |
2004 |
|
Thrombocythemia, Essential
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
We studied neutrophil CD177 mRNA levels in normal subjects and in 235 patients with Ph-negative chronic myeloproliferative disorders (CMD), including PV, essential thrombocythaemia and myelofibrosis with myeloid metaplasia.
|
15327515 |
2004 |
|
Thrombocythemia, Essential
|
0.100 |
Biomarker
|
disease |
BEFREE |
PRV-1, erythroid colonies and platelet Mpl are unrelated to thrombosis in essential thrombocythaemia.
|
15461629 |
2004 |
|
Thrombocythemia, Essential
|
0.100 |
Biomarker
|
disease |
BEFREE |
It can be concluded that PRV-1 positive patients appear to suffer from a more aggressive disorder with increased risk for vascular complications and a greater need for platelet-lowering therapy, compared with PRV-1 negative ET patients.
|
14617016 |
2003 |
|
Thrombocythemia, Essential
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
EECs were observed in 14 of 14 patients with PV and 4 of 12 with ET, and increased granulocyte PRV-1 mRNA levels were found in 9 of 13 patients with PV and 2 of 12 with ET.
|
12515724 |
2003 |
|
Thrombocythemia, Essential
|
0.100 |
Biomarker
|
disease |
BEFREE |
Of the ET patients 12 of 58 (21%) were PRV-1 positive and 19 of 58 (33%) demonstrated subnormal plasma EPO.
|
12756017 |
2003 |
|
Thrombocythemia, Essential
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
The overexpression of PRV-1 seems to be a useful tool for discriminating ET and PV from ST and SE, thus offering an innovative diagnostic approach on the basis of the detection of positive diagnostic criteria instead of exclusion criteria.
|
12377969 |
2002 |
|
Thrombocythemia, Essential
|
0.100 |
AlteredExpression
|
disease |
LHGDN |
The overexpression of PRV-1 seems to be a useful tool for discriminating ET and PV from ST and SE, thus offering an innovative diagnostic approach on the basis of the detection of positive diagnostic criteria instead of exclusion criteria.
|
12377969 |
2002 |
|
Thrombocythemia, Essential
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Moreover, PRV-1 is not expressed in mononuclear cells from patients with chronic myelogenous leukemia (n = 4) or acute myelogenous leukemia (n = 5) or in granulocytes from patients with essential thrombocythemia (n = 4) or secondary erythrocytosis (n = 4).
|
10753836 |
2000 |